Fair value · Legend Biotech Corp (LEGN) · updated 2026-10-03 · from 20-F FY2025
Legend Biotech trades at $18.62. We are not reading assumptions out of that price: our price is for one ADS, which represents 2 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and LEGN’s growth history are all as reported.
The filing behind these numbers
Legend Biotech Corp- Revenue
- $1.0B
- Diluted EPS
- $-0.81
- Free cash flow
- $-128.8M
- operating cash flow − capital expenditure
- Diluted shares
- 368.6M
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-10 · accession 0001801198-26-000008
Open this filing on sec.govNeed LEGN data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.